This episode of Digital Pathology Today™ our guest is Brandon Suh, MD, CEO of Lunit.   

Conquering cancer through Artificial Intelligence is the goal of our guest this week on Digital Pathology today. We're talking with Brandon Suh, MD, CEO of Lunit, a South Korean company creating applications utilizing Artificial Intelligence in both digital pathology as well as radiology.

 Lunit stands for “learning unit,” which is fundamental to the company's philosophy which embodies the belief that they can learn just about anything and is foundational to the Artificial intelligence, which involves continuous learning.

 The company has developed algorithms focusing on disease screening in the areas of mammography and chest X-ray in radiology and predictive and prognostic markers in digital pathology - in particular an AI based algorithm for immunotherapy, which outperforms the current standard of care.

 Lunit is looking to capitalize on the growing trend of Artificial Intelligence in medicine.

Brandon Suh has a background as a medical doctor and a proven track record in both medical expertise and business management.  

Brandon studied medicine at Seoul National University College of Medicine and is a board certified physician in Family Medicine, trained at Seoul National University Hospital. Prior to medical school, he graduated from KAIST with a bachelor’s degree in Biological Sciences. He has also received master’s degrees in both Public Health (MPH) and Business Administration (MBA). Brandon has a deep passion for medical research with much experience in both basic and clinical research, having published many articles in world-renowned journals like Hepatology and Annals of Oncology.